Daily Stock Analysis, EDC, EDAP TMS SA -ADR, priceseries

EDAP TMS SA -ADR. Daily Stock Analysis
Stock Information
Open
79.34
Close
77.56
High
79.41
Low
77.37
Previous Close
79.01
Daily Price Gain
-1.45
YTD High
89.91
YTD High Date
Apr 17, 2019
YTD Low
58.41
YTD Low Date
Jan 3, 2019
YTD Price Change
15.09
YTD Gain
24.16%
52 Week High
100.03
52 Week High Date
Jul 25, 2018
52 Week Low
54.89
52 Week Low Date
Oct 29, 2018
52 Week Price Change
-15.48
52 Week Gain
-16.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
53.80
Feb 24. 2017
68.73
36 Trading Days
27.75%
Link
LONG
Jul 11. 2017
86.44
Aug 9. 2017
98.58
21 Trading Days
14.05%
Link
LONG
Aug 21. 2017
98.20
Sep 5. 2017
103.64
10 Trading Days
5.54%
Link
LONG
Dec 27. 2017
119.98
Jan 30. 2018
153.45
22 Trading Days
27.89%
Link
LONG
Jan 4. 2019
64.84
Feb 7. 2019
77.66
23 Trading Days
19.76%
Link
LONG
Jun 18. 2019
73.36
Jul 5. 2019
78.13
12 Trading Days
6.50%
Link
Company Information
Stock Symbol
EDC
Exchange
NASDAQ
Company URL
http://www.edap-tms.com
Company Phone
69120 VAULX EN VELIN I0
CEO
Marc Oczachowski
Headquarters
-
Business Address
PARC D'ACTIVITES LA POUDRETTE LAMARTINE, 4 RUE DU DAUPHINE
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0001041934
About

Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. This division also leases equipment; sells disposables and spare parts; and offers maintenance services. The UDS division develops, manufactures, markets, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. It offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. This division also leases lithotripters; sells disposables and spare parts; and provides maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is based in Vaulx-en-Velin, France.